The GRABS trial is the first randomized controlled study examining tirzepatide (a dual GIP/GLP-1 receptor agonist) as adjuvant therapy in patients who remain obese — defined as BMI ≥30 kg/m² — at least 12 months after Roux-en-Y gastric bypass. The pilot cohort of 28 patients (82% female, median age 42, baseline randomization BMI of 36.0 kg/m²) is randomized 1:1 to 24 weeks of tirzepatide plus standard care versus standard care alone, with total percent weight change as the primary endpoint.
Persistent or recurrent obesity after bariatric surgery affects roughly 20-30% of RYGB patients and represents one of the most clinically frustrating gaps in metabolic medicine — a population that has already accepted surgical risk yet plateaus well above goal weight. GLP-1 receptor agonists have independently demonstrated 15-22% weight loss in non-surgical populations, but their pharmacodynamic interaction with the dramatically altered gut anatomy and incretin physiology post-RYGB is genuinely unknown territory. Tirzepatide's dual-agonism makes it a particularly interesting candidate here, since RYGB already amplifies endogenous GLP-1 secretion.
The critical caveat: with only 28 evaluable patients, this is explicitly a proof-of-concept signal trial — powered for feasibility and preliminary effect-size estimation, not definitive efficacy conclusions. The open-label design also introduces performance bias risk. Still, generating the first causal-inference data in this neglected subpopulation is a meaningful, if incremental, contribution that should rightly inform the design of adequately powered phase III work.